Medicus Pharma (NASDAQ:MDCX – Get Free Report) was upgraded by investment analysts at Brookline Capital Management to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.
Separately, Maxim Group assumed coverage on shares of Medicus Pharma in a research report on Tuesday, December 17th. They issued a “buy” rating and a $10.00 price target for the company.
Get Our Latest Report on Medicus Pharma
Medicus Pharma Stock Performance
About Medicus Pharma
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
See Also
- Five stocks we like better than Medicus Pharma
- What Are Dividend Achievers? An Introduction
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- What is Forex and How Does it Work?
- 2 Drone Stocks Surging from Increased Media Attention
- What is Short Interest? How to Use It
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
